ATE339503T1 - Cardiotrophin und verwendung davon - Google Patents

Cardiotrophin und verwendung davon

Info

Publication number
ATE339503T1
ATE339503T1 AT95921220T AT95921220T ATE339503T1 AT E339503 T1 ATE339503 T1 AT E339503T1 AT 95921220 T AT95921220 T AT 95921220T AT 95921220 T AT95921220 T AT 95921220T AT E339503 T1 ATE339503 T1 AT E339503T1
Authority
AT
Austria
Prior art keywords
chf
disorders
neurological
activity
isolated
Prior art date
Application number
AT95921220T
Other languages
English (en)
Inventor
Joffre Baker
Kenneth Chien
Kathleen King
Diane Pennica
William Wood
Original Assignee
Genentech Inc
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/233,609 external-priority patent/US5534615A/en
Application filed by Genentech Inc, Univ California filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE339503T1 publication Critical patent/ATE339503T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
AT95921220T 1994-04-25 1995-04-06 Cardiotrophin und verwendung davon ATE339503T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/233,609 US5534615A (en) 1994-04-25 1994-04-25 Cardiac hypertrophy factor and uses therefor
US08/286,304 US5571893A (en) 1994-04-25 1994-08-05 Cardiac hypertrophy factor

Publications (1)

Publication Number Publication Date
ATE339503T1 true ATE339503T1 (de) 2006-10-15

Family

ID=26927082

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95921220T ATE339503T1 (de) 1994-04-25 1995-04-06 Cardiotrophin und verwendung davon

Country Status (10)

Country Link
US (5) US5624806A (de)
EP (1) EP0755446B1 (de)
JP (1) JP3906314B2 (de)
AT (1) ATE339503T1 (de)
CA (1) CA2188017C (de)
DE (1) DE69535221T2 (de)
DK (1) DK0755446T3 (de)
ES (1) ES2276393T3 (de)
MX (1) MX9604985A (de)
WO (1) WO1995029237A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6288034B1 (en) * 1995-01-24 2001-09-11 Martinex R & D Inc. Recombinant human alpha-fetoprotein as an immunosuppressive agent
US5965528A (en) 1991-09-27 1999-10-12 Mcgill University Recombinant human alph-fetoprotein as an immunosuppressive agent
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US7258983B2 (en) * 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
US5869274A (en) * 1995-08-09 1999-02-09 Zymed Laboratories, Inc. Immuno-histochemical method that reduces background staining
WO1997030146A2 (en) * 1996-02-14 1997-08-21 Genentech, Inc. Cardiotrophin and uses therefor
AU768995B2 (en) * 1996-02-14 2004-01-15 Genentech Inc. Cardiotrophin and uses therefor
US5741772A (en) * 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
AU736707B2 (en) 1997-06-11 2001-08-02 Anaphore, Inc. Trimerising module
US6875567B1 (en) 1997-11-10 2005-04-05 Genentech, Inc. Method of detecting cardiac hypertrophy through probe hybridization and gene expression analysis
US6610480B1 (en) * 1997-11-10 2003-08-26 Genentech, Inc. Treatment and diagnosis of cardiac hypertrophy
EP1064382B1 (de) 1998-03-17 2008-08-20 Genentech, Inc. Zu vegf und bmp1 homologe polypeptide
GB9808796D0 (en) * 1998-04-24 1998-06-24 Rowett Research Services Limit Antithrombotic agents
US7208576B2 (en) * 1999-01-06 2007-04-24 Merrimack Pharmaceuticals, Inc. Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
US6656474B1 (en) * 1999-01-15 2003-12-02 Regeneron Pharmaceuticals, Inc. Methods of using a neurotrophin and its analogues for the treatment of gastrointestinal hypomotility disorders
ATE295963T1 (de) * 1999-01-21 2005-06-15 Genentech Inc Zusammensetzungen sowie verfahren zur diagnose und behandlung von tumorerkrankungen
EP1161533A1 (de) * 1999-03-09 2001-12-12 Atlantic Biopharmaceuticals, Inc. EXPRESSION VON HUMANEM ALPHA-FETOPROTEIN IN SäUGETIERZELLEN
ATE376837T1 (de) * 1999-07-12 2007-11-15 Genentech Inc Stimulierung oder hemmung von angiogenese und herzvaskularisierung mit tumor nekrose faktor ligand/rezeptor homologen
US6534300B1 (en) 1999-09-14 2003-03-18 Genzyme Glycobiology Research Institute, Inc. Methods for producing highly phosphorylated lysosomal hydrolases
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
IL150987A0 (en) 2000-02-11 2003-02-12 Genentech Inc Novel inhibitor of hepatocyte growth factor activator for use in modulation of angiogenesis and cardiovascularization
EP2792747A1 (de) 2000-06-23 2014-10-22 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
EP2075253A1 (de) 2000-06-23 2009-07-01 Genentech, Inc. Methoden und Verbindungen zur Diagnose und Behandlung von Krankheiten, an denen Angiogenese beteiligt ist
WO2002099386A2 (en) * 2001-06-07 2002-12-12 Proligo Llc Microcalorimetric detection of analytes and binding events
US20030224984A1 (en) * 2001-06-20 2003-12-04 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
ES2200646B1 (es) 2001-09-21 2005-05-01 Fundacion Para La Investigacion Medica Aplicada Uso de la cardiotrofina en enfermedades hepaticas.
US6905856B2 (en) 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US6800472B2 (en) 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
CN1812996A (zh) * 2003-06-25 2006-08-02 渥太华健康研究所 心营养素调节干细胞增殖的用途
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20090042795A1 (en) * 2007-06-05 2009-02-12 Pasan Fernando Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation
WO2009036349A1 (en) * 2007-09-12 2009-03-19 Anaphore, Inc. Hsp70-based treatment for autoimmune diseases
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
US20110086770A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Combinatorial Libraries Based on C-type Lectin-like Domain
CA2826114A1 (en) * 2011-02-01 2012-08-09 Fate Therapeutics, Inc. Cardiotrophin related molecules for enhanced therapeutics

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS552071A (en) * 1978-06-21 1980-01-09 Kuzumaki Ringiyou Kk Turnery working method and its device
JPS5520721A (en) * 1978-07-31 1980-02-14 Nippi:Kk Separation of biologically active material from hematopiesis tissue of domestic animal
US4339441A (en) * 1981-10-30 1982-07-13 Sumner M. Kalman Cardioactive factor
US5017375A (en) * 1982-11-24 1991-05-21 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5242798A (en) * 1983-07-21 1993-09-07 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US4900811A (en) * 1983-07-21 1990-02-13 Scripps Clinic And Research Foundation Synthetic polypeptides corresponding to portions of proteinoids translated from brain-specific mRNAs, receptors, methods and diagnostics using the same
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
EP0233838A3 (de) * 1986-02-04 1990-01-31 Incyte Pharmaceuticals, Inc. Neuriten stimulierender Faktor und Prozess für seine Herstellung
US5218094A (en) * 1986-08-07 1993-06-08 Fidia, S.P.A. Neuronotrophic factor derived from mammalian brain tissue
US4923696A (en) * 1987-05-04 1990-05-08 Baylor College Of Medicine Method to prepare a neurotrophic composition
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5141856A (en) * 1989-01-05 1992-08-25 Synergen, Inc. Expression of purified ciliary neurotrophic factor
WO1990009399A1 (en) * 1989-02-15 1990-08-23 Ono Pharmaceutical Co., Ltd. New neurotrophic factor
US5215969A (en) * 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
JP2829755B2 (ja) * 1989-12-27 1998-12-02 株式会社第一ラジオアイソトープ研究所 抗ヒト心筋ｃプロテインモノクローナル抗体及び該抗体を産生するハイブリドーマ
US5214031A (en) * 1990-05-09 1993-05-25 Yoko Uchida Growth-inhibitory factor obtained from human brain
JP2904935B2 (ja) * 1990-10-19 1999-06-14 武田薬品工業株式会社 神経栄養活性抑制物質
US5202428A (en) * 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
US6511823B1 (en) * 1990-08-20 2003-01-28 American Cyanamid Corporation Heparin binding neurotrophic factor gene sequence
US5210026A (en) * 1990-08-20 1993-05-11 American Cyanamid Company Human mk gene and method of expression
US5284932A (en) * 1990-09-07 1994-02-08 The Cleveland Clinic Foundation Process for purifying and characterizing myotrophia, a novel peptide that regulates myocardial growth
JPH04124198A (ja) * 1990-09-12 1992-04-24 Sumitomo Pharmaceut Co Ltd 神経栄養ペプチド誘導体
EP0563304A4 (en) * 1990-12-21 1994-09-14 Univ Case Western Reserve Neuronal cholinergic differentiation factor
US5767240A (en) * 1991-04-22 1998-06-16 The United States Of America As Represented By The Department Of Health And Human Services Activity-dependent neurotrophic factor
WO1992020797A1 (en) * 1991-05-20 1992-11-26 Case Western Reserve University Neurotrophic factor, preparation and uses thereof
PT100580A (pt) * 1991-06-12 1993-09-30 Regeneron Pharma Producao e recuperacao de neurotrofinas recombinantes
US5593857A (en) * 1991-08-23 1997-01-14 Scios Inc. Production of homogeneous truncated CNTF
WO1994005788A1 (fr) * 1991-09-12 1994-03-17 Sumitomo Pharmaceuticals Company, Limited Peptide neurotrophique
WO1993006116A1 (en) * 1991-09-20 1993-04-01 Syntex-Synergen Neuroscience Joint Venture Glial derived neurotrophic factor
CA2119580A1 (en) * 1991-10-01 1993-04-15 George Cachianes Production of gpa neurotrophic factor
WO1993018065A1 (fr) * 1992-03-10 1993-09-16 Mochida Pharmaceutical Co., Ltd. Substance proteique physiologiquement active
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
EP0662087B1 (de) * 1992-06-04 2003-10-01 The University Of Southern California Verfahren zur reinigung eines neurotrophen faktors aus pigmentiertem retinalen epithelgewebe
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor

Also Published As

Publication number Publication date
US5723585A (en) 1998-03-03
US5624806A (en) 1997-04-29
US5627073A (en) 1997-05-06
JP3906314B2 (ja) 2007-04-18
MX9604985A (es) 1998-05-31
ES2276393T3 (es) 2007-06-16
US5571675A (en) 1996-11-05
EP0755446A1 (de) 1997-01-29
DE69535221T2 (de) 2007-09-13
EP0755446B1 (de) 2006-09-13
US5679545A (en) 1997-10-21
WO1995029237A1 (en) 1995-11-02
CA2188017C (en) 2010-09-28
DE69535221D1 (de) 2006-10-26
AU697165B2 (en) 1998-10-01
CA2188017A1 (en) 1995-11-02
AU2635395A (en) 1995-11-16
DK0755446T3 (da) 2007-01-29
JPH09512427A (ja) 1997-12-16

Similar Documents

Publication Publication Date Title
DE69535221D1 (de) Cardiotrophin und verwendung davon
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE188969T1 (de) Peptidverbindungen und ihre therapeutische verwendung als inhibitoren von metalloproteinasen
ATE286126T1 (de) Glialmitogene faktoren, ihre herstellung und verwendung
ATE365796T1 (de) Tumornekrosefaktor-rezeptoren 6 alpha& 6 beta
PT939804E (pt) Neutroquina alfa
WO1996018738A3 (en) PROBIN TYROSINE KINASE (PYK2) ITS cDNA CLONING AND ITS USES
DE69724016D1 (de) Verwendung von anti-mikrotubuli mitteln zur behandlung von entzündlichen erkrankungen der atemwege
DE69435038D1 (de) Aktivin rezeptor-ähnliche kinase (alk), gehörend zur tgf rezeptorfamilie und/oder zur bmp rezeptorfamilie
DE3780972D1 (de) Verwendung von spezifischen n-methyl-d-aspartat-rezeptor-antagonisten zur praevention und behandlung von neurodegeneration.
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
EA200001247A1 (ru) N-связанные сульфонамиды n-гетероциклических карбоновых кислот или изостеры карбоновых кислот
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
DE3752062D1 (de) Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
DE69130497D1 (de) Neue Verwendung von 1-Alpha-hydroxylierten-19-nor-vitamin-D-Verbindungen zur Behandlung von Psoriasis
WO1997030146A3 (en) Cardiotrophin and uses therefor
DE69729735D1 (de) Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
DE69924284D1 (de) Verwendung von stimulatoren der neurotrophischen faktoren zur behandlung von neurodegenerativen ophthalmischen krankheiten
DE19681032D2 (de) Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen
DE3891306T1 (de) Konzentrator zur aufbereitung von nutzbaren mineralien
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
ATE286968T1 (de) Isolierung und verwendung von nukleinsäuremolekülen, welche für mitglieder der ssx-familie kodieren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0755446

Country of ref document: EP